Start Phase 2b/3 study with filgotinib in ulcerative colitis - Seite 3
Lesen Sie auch
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
1 im Artikel enthaltener WertIm Artikel enthaltene Werte